Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Kam Sprott"'
Autor:
Tanguy Y Seiwert, XiaoZhe Wang, Jana Heitmann, Vivian Villegas-Bergazzi, Kam Sprott, Stephen Finn, Esther O'Regan, Allan D Farrow, Ralph R Weichselbaum, Mark W Lingen, Ezra E W Cohen, Kerstin Stenson, David T Weaver, Everett E Vokes
Publikováno v:
PLoS ONE, Vol 9, Iss 7, p e102112 (2014)
BackgroundInduction chemotherapy is a common therapeutic option for patients with locoregionally-advanced head and neck cancer (HNC), but it remains unclear which patients will benefit. In this study, we searched for biomarkers predicting the respons
Externí odkaz:
https://doaj.org/article/8c508f0d8e494bdca4110695a9b7a55c
Autor:
Judy E. Garber, David T. Weaver, Laura C. Collins, Stuart J. Schnitt, Alan D. D'Andrea, XiaoZhe Wang, D. Allan Farrow, Kam Sprott, Brian M. Alexander
Purpose: To evaluate the prognostic utility of immunohistochemical assessment of key proteins in multiple DNA repair pathways in triple-negative breast cancer (TNBC; estrogen receptor negative, progesterone receptor negative, and HER2/neu negative by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::531ced791ea9d32b59a7a860f55bf346
https://doi.org/10.1158/1078-0432.c.6519155
https://doi.org/10.1158/1078-0432.c.6519155
Autor:
Judy E. Garber, David T. Weaver, Laura C. Collins, Stuart J. Schnitt, Alan D. D'Andrea, XiaoZhe Wang, D. Allan Farrow, Kam Sprott, Brian M. Alexander
Supplementary Figures S1-S2 and Supplementary Tables S1-S7.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9be09e486519d7fb9b078457234c263b
https://doi.org/10.1158/1078-0432.22442438.v1
https://doi.org/10.1158/1078-0432.22442438.v1
Autor:
Sebastian Bauer, Robin Lewis Jones, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, John Raymond Zalcberg, Yoon-Koo Kang, Albiruni Ryan Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, William Reichmann, Kam Sprott, Haroun Achour, Matthew L. Sherman, Rodrigo Ruiz-Soto, Jean-Yves Blay, Michael C. Heinrich
Publikováno v:
Journal of Clinical Oncology. 41:397784-397784
397784 Background: Ripretinib, a switch-control tyrosine kinase inhibitor (TKI), is indicated for patients (pts) with gastrointestinal stromal tumor (GIST) who received prior treatment with ≥3 TKIs, including imatinib. Sunitinib is approved for adv
Autor:
Yan Wang, Fricker Simon Paul, Kam Sprott, Philipp Uhlig, Kerstin David, Nicole Lange, Melanie Spyra
Publikováno v:
Journal of Histochemistry & Cytochemistry. 67:257-266
Chemokines and their receptors have been implicated in cancer biology. The CXCL12/CXCR4 axis is essential for the homing and retention of hematopoietic stem cells in bone marrow niches, and has a significant role in neonatal development. It is also i
Autor:
Pier Luigi Zinzani, Carole B. Miller, Stephanie Lustgarten, Kam Sprott, NgocDiep Le, Jonathan A. Pachter, Ian W. Flinn, Kirit M. Ardeshna, David T. Weaver, Nina D. Wagner-Johnston, Scott A. Tetreault
Publikováno v:
Blood. 132:4167-4167
Introduction: Indolent NHL (iNHL) remains largely incurable, with the majority of patients (pts) eventually becoming refractory to standard therapies, necessitating new effective and tolerable treatments. Duvelisib is an oral dual PI3K-δ,γ inhibito
Autor:
Constantine S. Tam, Kam Sprott, Jennifer R. Brown, Zsolt Nagy, Ian W. Flinn, Peter Hillmen, Ulrich Jaeger, Stephan Stilgenbauer, Bryone J. Kuss, Carol Moreno, Jonathan A. Pachter, Marco Montillo, Julio Delgado, NgocDiep Le, Stephanie Lustgarten, Paolo Ghia, Matthew S. Davids, Florence Cymbalista, David T. Weaver
Publikováno v:
Blood. 132:1856-1856
Introduction In CLL, the timing and selection of therapy is largely informed by disease stage, prognostic molecular features, tumor load, and patient (pt) performance status. Duvelisib (DUV) is a novel, oral, dual PI3K-δ,γ inhibitor in clinical dev
Autor:
Keith D. Merdek, Michael Stocum, Alison Skelley, William E. Pierceall, Yi Dong, Kam Sprott, Denis Smirnov, Walter P. Carney, Chunsheng Jiang, Jessie Lin
Publikováno v:
The Journal of Molecular Diagnostics. 15(2):149-157
Circulating tumor cells (CTCs) are shed from cancerous tumors, enter the circulatory system, and migrate to distant organs to form metastases that ultimately lead to the death of most patients with cancer. Identification and characterization of CTCs
Autor:
Eleni Tsiroyanni, Merrick I. Ross, Yan Wang, Robert H. Pierce, Lu Gan, Melinda L. Yushak, Kenneth F. Grossmann, Robert H.I. Andtbacka, Katie Niland, Mohammed M. Milhem, Sudha Parasuraman, Jean S. Campbell, Kam Sprott
Publikováno v:
Cancer Research. 78:613-613
Background: The CXCR4/CXCL12 pathway plays a central role in the trafficking of key immune cells in the tumor microenvironment (TME). X4P-001 is an oral, selective, allosteric CXCR4 inhibitor. We hypothesize that the disruption of CXCR4/CXCL12 signal
Autor:
Koen Van Eygen, Mercadal Santiago, Kam Sprott, Ngocdiep T. Le, Juan-Manuel Sancho, Andre Goy, Jonathan A. Pachter, Carla Casulo, Rod Johnson, David T. Weaver, Kamal Bouabdallah
Publikováno v:
Journal of Clinical Oncology. 36:7579-7579
7579Background: Duvelisib (DUV), an oral dual inhibitor of PI3K-d,g, is clinically active in hematologic malignancies, including follicular lymphoma (FL), CLL, and T cell lymphoma (Flinn, 2017). PI...